# Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

> **NCT03344328** · — · COMPLETED · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 67 (actual)

## Conditions studied

- Chemotherapy Induced Peripheral Neuropathy
- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT03344328
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-01-31
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344328, "Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03344328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*